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Give and Take? 
Human Bodies in Medicine and Research 
 
Response to Consultation of the Nuffield Council on Bioethics 
 
Shawn H.E. Harmon∗ 
 
The Nuffield Council recently established a Working Party chaired by Prof. Dame 
Marilyn Strathern to explore the ethical issues raised by the provision of bodily material 
for medical treatment and research.  Broad questions to be addressed include: 
 
• What motivates people to provide bodily material and what inducements or 
incentives are appropriate? 
• What constitutes valid consent? 
• What future ownership or control people should have over donated materials? 
• Are there ethical limits on how we try to meet (organ and tissue) demand? 
 
The Working Group met for the first time in January 2010.  A Consultation Paper was 
released in April 2010.1  The consultation closes on 13 July 2010.  A report outlining the 
Working Group’s findings, including recommendations for policy, is to be published in 
autumn 2011. 
 
The following represents a Response to the Consultation.  Registered in April 2010, the 
Response engages with just some of the themes articulated and questions posed in the 
Consultation Paper.  In particular, it addresses the questions of core values and possible 
governance structures applicable to the tissue and organ procurement setting.  The views 
expressed herein reflect the author’s personal opinions, and do not necessarily reflect any 
wider views or opinions of colleagues in SCRIPT or Innogen, the School of Law, or the 
University of Edinburgh. 
 
 
1. Nature of Human Bodily Material and First-in-Human Trials  
 
No response. 
 
2.  Purposes of Providing Bodily Material/Volunteering in a Trial  
 
No response. 
 
3. Ethical Values at Stake 
 
Q10: How should these values be prioritised or balanced against each other? Is there 
one value that should always take precedence over others? 
                                                          
∗  Research Fellow, InnoGen, ESRC Centre for Social and Economic Research on Innovation in 
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April 2010), available at 
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While all of these values – altruism, autonomy, dignity, justice, welfare-maximisation, 
reciprocity, and solidarity – are essential for the operation of a moral and rights-
conscious society (ie: a society striving to be a civil society), certain values are currently 
under-vindicated, not only in this setting but more broadly, and their better promotion 
and realisation would benefit society, patients and public health.  In particular, solidarity 
is very important and all too often given rhetorical recognition without any real practical 
weight.  Solidarity recognises our interconnectedness, the natural compassion that 
everyone feels (or should feel) toward others in view of the hardships and misfortunes of 
those others, and it is in compliance with noble values of dignity, respect and mutual 
help.  It emphasises community and mutual obligations.  Legislators and ethics 
committees and stakeholders in the public health and organ transplantation setting ought 
to give much more thought and weight to this value and the creativity that it undergirds 
when it comes to responding to public needs.  
 
Q12: Can there be a moral duty to provide human body material, either during life or 
after death? 
 
Based on the response to Q10, I feel that a duty to provide body material, certainly after 
death, may well be morally defended, and grounded in values such as solidarity, 
reciprocity, welfare-maximisation, justice, and the dignity of the vulnerable or needy (ie: 
the patient). 
 
4. Responding to Demand 
 
Q14: Is it right always to try to meet demand? Are some ‘needs’ or ‘demands’ more 
pressing than others? 
 
Conditions resulting in organ degradation and failure (and concomitant transplantation 
needs) are serious burdens on public health systems, on families, and indeed on ailing 
patients.  Given scarce resources, rising populations, and increasing environmental 
degradation, it is probably not morally necessary to meet every demand.  Rather, life-
saving, life-prolonging, and life-enhancing uses are more pressing than life-creating, for 
they have greater potential to increase public health and ease health resource pressures.  
Our greater moral responsibility is to ease suffering, facilitate (productive) functionality, 
and improve human wellbeing. 
Having made this distinction, however, the framing of the issue is of great 
importance.  It is preferable to start from the premise that transplantation, as a proven 
and cost-effective treatment option where it has been sufficiently developed,2 is (or 
should be) a favoured healthcare response to a variety of chronic and otherwise terminal 
conditions.  Used maximally, it could improve the health, functionality, productivity, and 
enjoyment of life of millions of people, and in doing so, could have a transformative 
effect on healthcare delivery and healthcare system efficiency. 
One might characterise the chronic shortage of transplantable organs and tissue 
as a purely social problem, but it is appropriate to characterise it as an acute moral issue; 
                                                          
2  Numerous studies have demonstrated that kidney transplantation is cheaper than, and improves 
longevity over, dialysis, as is the case with other forms of transplantation, such as liver and heart: see W. 
Winkelmayer et al., ‘Health Economic Evaluations: The Special Case of End-Stage Renal Disease 
Treatment’ (2002) 22 Med Decision Making 417-430, R. Adam et al., ‘Evolution of Liver Transplantation 
in Europe’ (2003) 9 Liver Transplant 1231-1243, D. Taylor et al., ‘2006 Report of the International Society 
for Heart and Lung Transplantation’ (2006) 25 J Heart Lung transplant 869-879, and others. 
  
an unethical and unjust state of affairs that represents a fatal shortcoming of the 
healthcare system as it currently exists.3 By framing the issue as a pressing moral matter, 
one strengthens the imperative to remedy it, and expands the range of possible 
(defensible) mechanisms for doing so, the ultimate aim being to promote human 
wellbeing. 
 
Q15: Should different forms of incentive, compensation or recognition be used to 
encourage people to provide different forms of bodily material? 
 
Absolutely.  The only way to maximise transplant programmes and maximally benefit 
public health is to adopt a multi-pronged, joined-up approach which more effectively and 
creatively links social/moral values, legal principles, and regulatory responses to 
particular medical problems, finding those areas of value convergence and adopting 
policy positions that vindicate those values while solving the particular (medical) problem 
to be addressed.  Obviously, this represents an impressive but not insurmountable 
policy-making challenge.  Such an integrated approach to organ/tissue procurement 
might properly include the following 5 components: 
 
1. Healthcare Professional Education: We must avoid poor or incomplete 
understanding of the costs, benefits, risks, and long-term consequences of 
transplantation for patients and for public health.  In addition to an increased 
focus on transplantation as a part of general medical education, all practicing 
physicians and nurses, especially those working in ICUs, Emergency Units, and 
Palliative Care Units,4 should undergo mandatory continuing professional 
development training (in person and virtual/online) relating to transplantation.  
In addition to being informed about the value of transplantation and its 
importance to public health and national goals, training should focus on donor 
identification (which must occur early), donor screening (so disease transmission 
or infection are minimised), donor maintenance (so that organs are obtained in a 
usable state), sensitive physician-patient/family interaction (so a facilitative 
environment is created and information can be better shared and assimilated), 
and organ retrieval (best practices for removing, handling, preserving/storing, 
and transporting organs). 
 
2. Public Education/Promotion: Multi-media public education and promotional 
campaigns, both national and regional,5 should be undertaken on an ongoing or 
rolling basis. A general campaign, realised through print, radio, television, and 
web media, could advance the following concepts and messages: 
 
• every individual bears duties grounded in solidarity and altruism to others 
in society and to the state; 
 
                                                          
3  Its moral foundation has also been recognized by others: see F. Cantarovich, ‘Reducing the 
Organ Shortage by Education and by Fostering a Sense of Social Responsibility’ (2003) 35 Transplantation 
Proceedings 1153-1155. 
4  For more on the value of ‘marginal donors’ like the elderly, minors, diabetics, those with ischemia 
or infection, and so on, see G. Abouna, ‘Organ Shortage Crisis: Problems and Possible Solutions’ (2008) 
40 Transplantation Proceedings 34-38. 
5  Such a 2-tiered approach is necessary so that nuances in local character and local reasons for 
suboptimal donation can be addressed, whether they are socio-cultural, religious, or otherwise: see S. Rizvi 
et al., ‘Improving Kidney and Live Donation Rates in Asia: Living Donation’ (2004) 36 Transplantation 
Proceedings 1894-1895. 
  
• duties extend to obligations to contribute to personal and public health 
and to the wellbeing of others, thereby improving national productivity; 
 
• transplantation is an important and integral part of effective modern 
healthcare and is contrary neither to any major religion, nor to traditional 
ethics; 
 
• every member of society is a potential donor and recipient (ie appeals to 
enlightened self-interest might highlight that the sharing of a personal 
resource, either during their life or after death or both, that is unique, may 
also benefit them in their lives); 
 
• clinical and social outcomes consequent to successful transplantations are 
typically favourable (and specific evidence might be provided); 
 
• the state and medical institutions are concerned with patient and public 
health, and risks to participants will always be minimised through strict 
safety measures and oversight. 
 
This general campaign should be supplemented by campaigns targeting specific 
audiences. In particular, young people should be reached and encouraged so that 
health solidarity and transplantation/donation become a part of the national 
social fabric. 
 
3. Transplant Coordination Service: A national Transplant Coordination Service 
(TCS), organised into central and local/institutional branches, should be created 
so that trained and motivated transplantation experts could manage and advance 
transplantation medicine.  The central/national Secretariat could: 
 
• serve as the interface between the national government and the 
transplantation community and set broad/national transplantation policy 
(including conducting public engagement exercises); 
 
• erect and keep current national technical standards (through the hosting 
of expert consensus conferences); 
 
• undertake oversight and enforcement operations (certifying professionals, 
licensing hospitals, recertifying through site and records inspections, 
auditing institutions and practitioners for compliance with ethical 
allocation practices, generally ensuring compliance with the statutory 
scheme); 
 
• undertake the proposed professional education and public promotion 
campaigns, bringing its unique perspective and evidence to bear (and it 
might provide a 24-hour transplantation telephone hotline for those 
seeking information6); and 
 
                                                          
6  Such a hotline has proved a very useful resource in Spain: see R. Matesanz & B. Dominguez-Gil, 
‘Strategies to Optimize Deceased Organ Donation’ (2007) 21 Transplantation Reviews 177-188. 
  
• facilitate (and coordinate) equitable organ sharing between institutions 
and across borders. 
 
The local/institutional branches of the TCS would comprise individual 
Transplant Coordinators (ie: physicians and nurses acting on a part-time basis 
outside of their medical duties and reporting to the central authority).  Transplant 
Coordinators, rather than treating physicians or nurses, could: 
 
• continuously monitor potential donors; 
 
• approach patients and families about donation and transplantation;7 
 
• provide information to individuals, assist in patient identification, 
articulate and resolve potential conflicts between being a patient and a 
potential donor; 
 
• obtain consent (where applicable); 
 
• coordinate the various actors involved in performing transplantations, 
and ensure the provision of adequate follow-up to both recipient and 
donor (if living) or family (if cadaveric). 
 
A TCS would go a long way toward educating and obtaining evidence from the 
public, thereby permitting better, evidence-based policies in the future.  Through 
its monitoring and enforcement of transplant standards, a TCS would enhance 
patient safety, a value already explicitly considered of vital importance.  It would 
also make transplant medicine more transparent and responsive, and therefore 
more democratic. 
 
4. Opt-Out System (Cadaveric Donation): A nation-wide opt-out system for 
cadaveric donation should be instituted whereby every member of society is 
automatically a contributor to transplant medicine.8  Thus, unless one specifically 
opts-out via a written form provided to a TCS coordinator and entered onto a 
central registry maintained by the TCS, one is automatically a member of the 
donation scheme such that when one dies, either naturally or by an accident, any 
organs and tissue of suitable quality are made available to patients within that 
region.  Those who opt out would be issued an opt-out card to be carried on 
their person.  While some will complain that an opt-out approach diminishes, or 
is incompatible with, autonomy, in fact, it preserves autonomy and respect for 
the person insofar as every individual has the right, at any time, and after the 
consideration of as much or as little information as desired, to make an ‘informed 
choice’, to express that choice, and to have both respected.  Ultimately, it strikes 
a reasonable balance between individual choice and promotion of the public 
                                                          
7  It has been reported that the Hong Kong Transplant Coordination Service, established in 1988, 
has enjoyed great success, raising the procurement rate from 10% to 40%: T. Chan, ‘Donor Shortage in 
Organ Transplantation: Perspectives from Hong Kong’ (2002) 34 Transplantation Proceedings 2558-2559. 
8  This is sometimes called ‘presumed consent’.  I prefer not to use ‘presumed consent’ because this 
is an unhelpful fiction; we are not presuming consent, we are disposing of the need for consent, and 
extending to individuals and families the possibility of exercising ‘informed refusal’ through the act of 
withdrawal. 
  
good.  It is impossible to say who might object to an opt-out approach; this is an 
area which demands greater empirical work.9 
 
5. Rewarded Donation System (Living Donation): It is fair to characterise live 
organ/tissue donation as an intimate form of social interaction which should 
result in some form of reciprocity.10 In short, some benefits should be enjoyed by 
all participants (eg the public, the recipient, and the donor), and this seems to be 
the most fair and equitable approach (much more so than purely altruistic 
donation, which has proven wholly incapable of meeting demand).11 While it has 
been claimed that the near universal rejection of a commercialised organ trade is 
gradually eroding,12 it remains a controversial and, to many, an unpalatable 
option for increasing procurement rates.13 As such – and given the existing 
international rejection of organ markets,14 as well as the touchstones of duty, 
solidarity, and rewarded altruism – a non-market approach to living donation is 
favoured.  Survey evidence suggests that some recognition is warranted.  This 
recognition could come in several forms, some of them compensatory, and it 
might include the following: 
                                                          
 
• Social Recognition: While one might hope for donation decisions to be 
purely solidaristic, it is not necessary to demand unbridled altruism of 
people, and its absence need not taint the act.  Recognition might take 
several forms, from letters of appreciation from government and/or 
recipient (anonymised or not), to certificates of special recognition from 
the government and/or health authorities, to inclusion on a publicly 
searchable national list of live donors (for those wishing to waive their 
privacy rights). 
 
• Enhanced Organ/Tissue Eligibility: Live donors, or a designated member of 
their immediate family, might automatically become eligible for ‘enhanced 
consideration’ should they develop a need for a transplantable organ or 
tissue.  Their particulars could be entered onto national and regional 
registries until such time as they might have to enter a waiting list for a 
specific transplant, at which time they would be ranked as if they had 
been entered on the date of their donation. 
 
9  Many countries have adopted opt-out schemes, including Austria, Belgium, Spain, and Sweden, 
with varying degrees of success. 
10  M. Schweda & S. Schicktanz, ‘Public Ideas and Values Concerning the Commercialization of 
Organ Donation in Four European Countries’ (2008) 68 Soc. Sci. Med. 1129-1136. 
11  In fact, demands for improved social recognition of donors is not new: see R. Veatch, ‘Routine 
Inquiry About Organ Donation: An Alternative to Presumed Consented’ (1991) 325 New Eng J Med 
1246-1249. 
12  M. Schweda & S. Schicktanz, note 10.  Iran permits organ sales: see A. Daar, ‘The Case for a 
Regulated System of Living Kidney Sales’ (2006) 2 Nature Clin. Nephrology 600-601. And see C. Erin & J. 
Harris, ‘An Ethical Market in Human Organs’ (2003) 29 JME 137-138, who advocate a brokered market 
approach. 
13  See these studies: M. Schweda & S. Schicktanz, note 10, and C. Mehmet et al., ‘How to Improve 
Organ Donation: Results of the ISHLT/FACT Poll’ (2003) 22 J Heart Lung Transplant 389-410. 
14  See Principles 5 and 6 of the WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation, 
Document EB123/5, WHO Executive Board, 26 May 2008. 
  
• Improved Health Insurance Coverage: Live donors, or a designated member of 
their immediate family, might automatically become eligible for improved 
health insurance. 
 
• Related Expenses: Live donors should receive financial compensation in the 
form of paid travel (and, if necessary, hotel) expenses for pre-op testing 
and post-op follow-up visits to the hospital, paid nutrition allowances for 
days spent travelling, wage continuation coverage for the duration of their 
convalescence, and a nominal, legislatively set financial award for the pain 
and inconvenience they will suffer as a result of surgery. This 
compensation might be contributed to by the state and by the private 
insurers of employers and hospitals. 
 
This multiple reward system, built into the law, could reverse trends with respect 
to availability of quality transplantable organs from living donors (which are the 
best organs and the most likely to result in success and long-term health 
outcomes).15 
 
It is important to note that no singular approach is likely to have any significant impact 
with respect to reversing current trends.  Further, and importantly, there is very little 
evidence for claiming that any one of the above strategies will work.  However, 
combined, they should have palpable positive effects.  Social research in this area would 
be useful. 
 
5. The Role of Consent 
 
Q25: What part should family members play in deciding whether bodily material may 
be used after death (a) where the deceased person’s wishes are known, and (b) 
where they are unknown? Should family members have any right of veto. 
 
This is a very sensitive issue, and one which places healthcarers in a difficult position.  
Clarity in the law might assist them.  Obviously, families should (and do) play a part in 
these decisions.  However, where the deceased person’s wishes are known (eg: contained 
in an Advanced Directive or Will), the family should have no veto, unless there is highly 
persuasive evidence that the deceased person’s wishes have changed from those 
contained in the legal instrument.  Where the deceased person’s wishes are unknown, the 
position of the family (assuming it is unified) might have greater weight, but if it is 
divided, public authorities should empower healthcarers to presume consent for this will 
ultimately benefit public health and vindicate a range of values. 
 
6.  Ownership and Control 
 
Q26: To whom, if anyone, should a dead body or its parts belong? 
 
This is a difficult question which probably deserves empirical research.  There is some 
justification for adopting the position that the dead body (and its parts) are public goods 
and part of the person’s ‘giving back’ to society and comporting to solidarity.  This may 
be justified where the body (or its parts) are destined to serve patients and public health 
                                                          
15  See G. Abouna et al., ‘The Living Unrelated Donor: A Viable Alternative for Renal 
Transplantation’ (1988) 20 Transplantation Proceedings 802-804, and more. 
  
                                                          
directly, but probably less so where it is desired for research by private or profit-oriented 
entities. 
 
7.  Any Other Issues 
 
Q30: Are there any other issues, connected with our Terms of Reference, that you 
would like to draw to our attention? 
 
While it is important to recognise that the UK is a heterogeneous multicultural society, 
one might note that emerging empirical data in jurisdictions that have traditionally been 
wary of donation (particularly cadaveric donation) and transplantation suggests that 
people support this element of public health.  One example is China (from which the 
UK receives a lot of immigrants).  A variety of large surveys conducted in Hong Kong 
and mainland China expose a commonly shared concern for, or ‘solidarity’ with, other 
humans; certainly family members, but also other vulnerable people or groups. 16 
 
 
16  See T. Chan, note 7, B. Cheng et al., ‘An Overview of Attitudes Towards Organ Donation in 
Hong Kong’ (2005) 7 HK J Nephrol 77-81, Y-F. Tong et al., ‘Needs and Experiences of Hong Kong 
Chinese Cadaveric Organ Donor Families’ (2006) 8 HK J Nephrol 24-32, L. Zhang et al., ‘Knowledge and 
Willingness Toward Living Organ Donation: A Survey of Three Universities in Changsha, Hunan 
Province, China’ (2007) 39 Transplantation Proceedings 1303-1309. 
